IL28RA polymorphism (rs10903035) is associated with insulin resistance in HIV/HCV-coinfected patients

Journal of Viral Hepatitis

Volumn 21, Issue 3, 2014, Pages 189-197

  Jimenez Sousa M A ^a   Berenguer, J ^b   Fernandez Rodriguez A ^a   Micheloud, D ^b   Guzman Fulgencio M ^a   Miralles, P ^b   Pineda Tenor, D ^a   Garcia Alvarez M ^a   Lopez J C ^b   Aldamiz Echevarria T ^b   Carrero, A ^b   Resino, Salvador ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

AIDS; hepatitis C; insulin resistance; liver fibrosis; SNPs

Indexed keywords

INTERLEUKIN 28; INTERLEUKIN 28 RECEPTOR ALPHA; INTERLEUKIN 28B; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASSAY; CROSS-SECTIONAL STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE HOMEOSTASIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL;

AIDS; HEPATITIS C; INSULIN RESISTANCE; LIVER FIBROSIS; SNPS;

ADULT; CD4 LYMPHOCYTE COUNT; COINFECTION; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; INSULIN RESISTANCE; INTERLEUKINS; MALE; ODDS RATIO; POLYMORPHISM, GENETIC; RECEPTORS, CYTOKINE; VIRAL LOAD;

EID: 84892783830     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12130     Document Type: Article

References (51)

1. Lo Re V 3rd, Kostman JR, Amorosa VK,. Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century. Clin Liver Dis 2008; 12 (3): 587-609, ix.
2. Lopez-Dieguez M, Montes ML, Pascual-Pareja JF, et al,. The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. AIDS 2011; 25 (7): 899-904.
3. Macias J, Berenguer J, Japon MA, et al,. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009; 50 (4): 1056-1063.
4. Negro F, Sanyal AJ,. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int 2009; 29 (Suppl 2): 26-37.
5. Younossi ZM, McCullough AJ,. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int 2009; 29 (Suppl 2): 3-12.
6. Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E,. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther 2013; 37 (6): 647-652.
7. Samaras K,. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection. J Antimicrob Chemother 2008; 61 (2): 238-245.
8. Calza L, Manfredi R, Pocaterra D, Chiodo F,. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy. J Infect 2008; 57 (1): 16-32.
9. Triant VA, Lee H, Hadigan C, Grinspoon SK,. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92 (7): 2506-2512.
10. Eslam M, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M,. Use of HOMA-IR in hepatitis C. J Viral Hepatitis 2011a; 18 (10): 675-684.
11. Heim MH,. Interferons and hepatitis C virus. Swiss Med Wkly 2012; 142: w13586.
12. Mohr A, Chatain N, Domoszlai T, et al,. Dynamics and non-canonical aspects of JAK/STAT signalling. Eur J Cell Biol 2012; 91 (6-7): 524-532.
13. Hayes CN, Imamura M, Aikata H, Chayama K,. Genetics of IL28B and HCV-response to infection and treatment. Nat Rev Gastroenterol Hepatol 2012; 9 (7): 406-417.
14. Kelly C, Klenerman P, Barnes E,. Interferon lambdas: the next cytokine storm. Gut 2011; 60 (9): 1284-1293.
15. Thomas E, Gonzalez VD, Li Q, et al,. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012; 142 (4): 978-988.
16. Levy DE, Marie IJ, Durbin JE,. Induction and Function of Type I and III Interferon in Response to Viral Infection. Curr Opin Virol 2011; 1 (6): 476-486.
17. Marcello T, Grakoui A, Barba-Spaeth G, et al,. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131 (6): 1887-1898.
18. Jimenez-Sousa MA, Fernandez-Rodriguez A, Guzman-Fulgencio M, Garcia-Alvarez M, Resino S,. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med 2013; 11 (1): 6.
19. Clark PJ, Thompson AJ, Zhu Q, et al,. The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. Dig Dis Sci 2012; 57 (8): 2213-2221.
20. Guzman-Fulgencio M, Berenguer J, Garcia-Alvarez M, et al,. IL28B polymorphisms are associated with severity of liver disease in human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus. J Infect 2013; 66 (2): 170-178.
21. Bochud PY, Bibert S, Kutalik Z, et al,. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 2012; 55 (2): 384-394.
22. Barreiro P, Pineda JA, Rallon N, et al,. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. J Infect Dis 2011; 203 (11): 1629-1636.
23. Rembeck K, Alsio A, Christensen PB, et al,. Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLoS One 2012; 7 (1): e29370.
24. Ohnishi M, Tsuge M, Kohno T, et al,. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. J Gastroenterol 2012; 47 (7): 834-844.
25. Agundez JA, Garcia-Martin E, Maestro ML, et al,. Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. PLoS One 2012; 7 (5): e37998.
26. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R,. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 2007; 81 (14): 7749-7758.
27. Yang L, Luo Y, Wei J, He S,. Integrative genomic analyses on IL28RA, the common receptor of interferon-lambda1, -lambda2 and -lambda3. Int J Mol Med 2010; 25 (5): 807-812.
28. Jimenez-Sousa MA, Berenguer J, Rallon N, et al,. IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus/HCV coinfected patients. J Viral Hepatitis 2013; 20 (5): 358-366.
29. Scott RA, Lagou V, Welch RP, et al,. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet 2012; 44 (9): 991-1005.
30. Morris AP, Voight BF, Teslovich TM, et al,. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 2012; 44 (9): 981-990.
31. Manning AK, Hivert MF, Scott RA, et al,. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet 2012; 44 (6): 659-669.
32. Del Campo JA, Ampuero J, Rojas L, et al,. Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism. Aliment Pharmacol Ther 2013; 37 (1): 74-80.
33. Ciesla A, Bociaga-Jasik M, Sobczyk-Krupiarz I, et al,. IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C. World J Gastroenterol 2012; 18 (35): 4892-4897.
34. Petta S, Rosso C, Leung R, et al,. Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. Clin Gastroenterol Hepatol 2012; 11 (3): 311-317.
35. Stattermayer AF, Rutter K, Beinhardt S, et al,. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. J Hepatol 2012; 57 (3): 492-498.
36. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC,. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28 (7): 412-419.
37. Jacobs WH, Goldberg SB, Balint JA, et al,. Statement on outpatient percutaneous liver biopsy. Dig Dis Sci 1989; 34 (3): 322-323.
38. Lindsey J, Jones B,. Choosing among generalized linear models applied to medicad data. Stat Med 1998; 17: 59-68.
39. Fernandez-Rodriguez A, Rallon N, Berenguer J, et al,. Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. AIDS 2013; 27 (2): 163-173.
40. Eslam M, Aparcero R, Kawaguchi T, et al,. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 2011b; 34 (3): 297-305.
41. Ogawa E, Furusyo N, Murata M, et al,. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. J Hepatol 2012; 57 (3): 534-540.
42. Cui Q, Zhang YX, Su J, et al,. Genetic variation in IL28RA is associated with the outcomes of HCV infection in a high-risk Chinese population. Infect Genet Evol 2011; 11 (7): 1682-1689.
43. Zhang L, Jilg N, Shao RX, et al,. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol 2011; 55 (2): 289-298.
44. Brand S, Beigel F, Olszak T, et al,. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 2005; 289 (5): G960-G968.
45. Hiard S, Charlier C, Coppieters W, Georges M, Baurain D,. Patrocles: a database of polymorphic miRNA-mediated gene regulation in vertebrates. Nucleic Acids Res 2010; 38 (Database issue): D640-D651.
46. Velu VK, Ramesh R, Srinivasan AR,. Circulating MicroRNAs as Biomarkers in Health and Disease. J Clin Diagn Res 2012; 6 (10): 1791-1795.
47. Merchante N, Rivero A, de Los Santos-Gil I, et al,. Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients. Gut 2009; 58 (12): 1654-1660.
48. Ryan P, Berenguer J, Michelaud D, et al,. Insulin resistance is associated with advanced liver fibrosis and high body mass index in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2009; 50 (1): 109-110.
49. Duckworth WC,. Insulin degradation: mechanisms, products, and significance. Endocr Rev 1988; 9 (3): 319-345.
50. Probst A, Dang T, Bochud M, Egger M, Negro F, Bochud PY,. Role of hepatitis C virus genotype 3 in liver fibrosis progression-a systematic review and meta-analysis. J Viral Hepatitis 2011; 18 (11): 745-759.
51. Burton PR, Tobin MD, Hopper JL,. Key concepts in genetic epidemiology. Lancet 2005; 366 (9489): 941-951.